In lung cancer, increased levels of precursor-like T cells in responsive tumors have been observed after treatment, thus suggesting that PD-1 blockade therapy preferentially blocks the differentiation from precursor to terminally differentiated cells after effective treatment (74, 75). Here, PDCD1 is linked to lung cancer.